Similarly, TCGA (The Cancer Genome Atlas) RNASeq samples belonging to several human ADCs [colon (COAD), pancreatic (PAAD), and stomach (STAD)], subdivided into mutant- and WT-KRAS status, show that the mutant-KRAS-associated signature identified is also applicable across cancer contexts (p = 0.011 for COAD, N = 100 mutant KRAS and N = 211 WT; p = 2.83 × 10−7 for the PAAD, N = 127 mutant KRAS and N = 31 WT; and p = 0.05 for STAD, N = 18 mutant KRAS and N = 294 WT) (Fig. 5a). This evidence concerns the gene KRAS and cancer.